Dermatological uses of high-dose intravenous immunoglobulin

Archives of Dermatology

Volumn 134, Issue 1, 1998, Pages 80-86

  Jolles, Stephen ^a   Hughes, Jenny ^a   Wittaker, Sean ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOKINE; CYTOMEGALOVIRUS ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; RHESUS D ANTIBODY; STEROID;

ARTICLE; BULLOUS SKIN DISEASE; CHILL; CLINICAL PROTOCOL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; CYTOKINE RELEASE; DERMATOMYOSITIS; DRUG COST; DRUG MEGADOSE; DRUG SAFETY; EPIDERMOLYSIS BULLOSA ACQUISITA; FEVER; HEADACHE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MYALGIA; NAUSEA; PEMPHIGOID; PEMPHIGUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ALLERGY AND IMMUNOLOGY; AUTOIMMUNE DISEASES; CLINICAL PROTOCOLS; CONTROLLED CLINICAL TRIALS; DERMATOLOGIC AGENTS; DERMATOLOGY; DERMATOMYOSITIS; DRUG COSTS; EPIDERMOLYSIS BULLOSA ACQUISITA; HOME CARE SERVICES; HOSPITAL COSTS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; PATIENT CARE TEAM; PATIENT SELECTION; PEMPHIGOID, BULLOUS; PEMPHIGUS; QUALITY OF LIFE; SAFETY; SKIN DISEASES; SKIN DISEASES, VESICULOBULLOUS; STEROIDS; TIME FACTORS;

EID: 0031933548     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.134.1.80     Document Type: Article

References (54)

1. Cohn EJ, Strong LE, Hughes WL. Preparation and properties of serum and plasma proteins: a system for the separation into fractions of the protein and lipoprotein components of biological fluids. J Am Chem Soc. 1946;68:459-475.
2. Rütter GH. Requirements for safety and quality of intravenous immunoglobulin G preparations. J Neurol Neurosurg Psychiatry. 1994;57:2-5.
3. Yap PL. The viral safety of intravenous immune globulin. Clin Exp Immunol. 1996;104(suppl 1):35-43.
4. Mouthon L, Kaveri SV, Spalter SH, et al. Mechanisms of action of intravenous immune globulin in immune mediated diseases. Clin Exp Immunol. 1996;104 (suppl 1):3-9.
5. Lam L, Whitsett CF, McNicholl JM, Hodge TW, Hooper J. Immunologically active proteins in intravenous immunoglobulin. Lancet. 1993;342:678.
6. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med. 1992;326:107-116.
7. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 1994;94:1729-1735.
8. Basta M. Modulation of complement-mediated immune damage by intravenous immune globulin. Clin Exp Immunol. 1996;104:21-26.
9. Andersson J, Skansen-Saphir U, Sparrelid E, Andersson U. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol. 1996;104:10-21.
10. Jung T, Schauer U, Heusser C, Neumann C, Rieger C. Detection of intracellular cytokines by flow cytometry. J Immunol Methods. 1993;159:197-207.
11. Van Schaik IN, Lundkvist I, Vermeulen M, Brand A. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol. 1992;12:325-334.
12. Kondo N, Kasahara K, Kameyama T. Intravenous immunoglobulins suppress immunoglobulin production by suppressing calcium-dependent signal transaction through Fc gamma receptors in B lymphocytes. Scand J Immunol. 1994;40:37-42.
13. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE, Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet. 1984;2:765-768.
14. Hurez V, Kaveri SV, Mouhoub A, et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use (intravenous immunoglobulin, IVIg). Ther Immunol. 1994;1:269-277.
15. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf. 1993;9:254-262.
16. Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol. 1994;97(suppl 1):79-83.
17. Comenzo RL, Malachowski ME, Meissner HC, Fulton DR, Berkman EM. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr. 1992;120:926-928.
18. Thomas MJ, Misbah SA, Chapel HM, Jones M, Elrington G, Newsom-Davis J, Hemolysis after high-dose intravenous Ig. Blood. 1993;82:3789.
19. Ben-Chetrit E, Putterman C. Transient neutropenia induced by intravenous immune globulin. N Engl J Med. 1992;326:270-271.
20. Lassiter HA, Bibb KW, Bertolone SJ, Patel CC, Stroncek DF. Neonatal immune neutropenia following the administration of immune globulin. Am J Pediatr Haematol Oncol. 1993;15:120-123.
21. Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol. 1993;50:137-139.
22. Kobosko J, Nicol P. Renal toxicity of intravenous immunoglobulin. Clin Nephrol. 1992;37:216-217.
23. Barton JC, Herrera GA, Galla JH, Bertoli LF, Work J, Koopman WJ. Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin. Am J Med. 1987;82:624-629.
24. Barucha C, McMillan JC. Eczema after intravenous infusion of immunoglobulin. BMJ. 1987;295:1141.
25. Chan-Lam D, Fitzsimons EJ, Douglas WS. Alopecia after immunoglobulin infusion. Lancet. 1987;1:1436.
26. Rodeghiero F, Castaman G, Vespignani M, Dini E, Bertazzoni M. Erythema multiforme after intravenous immunoglobulin. Blut. 1988;56:145.
27. Cherin P, Piette JC, Wechsler B, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol. 1994;21:1092-1097.
28. Saadeh C, Bridges W, Burwick F. Dermatomyositis: remission induced with combined oral cyclosporine and high-dose intravenous immune globulin. South Med J. 1995;88:866-870.
29. Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med. 1991;91:169-172.
30. Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med. 1991;91:162-168.
31. Cherin P, Herson S, Wechsler B, et al. Intravenous immunoglobulin for polymyositis and dermatomyositis [published correction appears in Lancet 1990;336:518]. Lancet. 1990;336:116.
32. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993-2000.
33. Bodemer C, Teillac D, Le Bourgeois M, Wechsler B, de Prost Y. Efficacy of intravenous immunoglobulins in sclerodermatomyositis. Br J Dermatol. 1990;123:545-546.
34. Collet E, Dalac S, Maerens B, Courtois JM, Izac M, Lambert D. Juvenile dermatomyositis: treatment with intravenous gammaglobulin. Br J Dermatol. 1994;130:231-234.
35. Barron KS, Sher MR, Silverman ED. Intravenous immunoglobulin therapy: magic or black magic. J Rheumatol Suppl. 1992;33:94-97.
36. Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis: four-year review of nine cases. Arch Dis Child. 1995;72:25-28.
37. De Vita S, D'Ascanio A, Bombardieri S. Use of high-dose intravenous immunoglobulins in the therapy of connectivitis: preliminary experience in 5 cases. Recenti Prog Med. 1991;82:603-606.
38. Beckers RC, Brand A, Vermeer BJ, Boom BW. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br J Dermatol. 1995;133:289-293.
39. Tappeiner G, Steiner A, High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid. J Am Acad Dermatol. 1989;20:684-685.
40. Messer G, Sizmann N, Feucht H, Meurer M. High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris. Br J Dermatol. 1995;133:1014-1016.
41. Humbert P, Derancourt C, Aubin F, Agache P. Effects of intravenous gammaglobuiin in pemphigus. J Am Acad Dermatol. 1990;22:326.
42. Bewley AP, Keefe M. Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy. Br J Dermatol. 1996;135:128-129.
43. Godard W, Roujeau JC, Guillot B, Andre C, Rifle G. Bullous pemphigoid and intravenous gammaglobulin. Ann Intern Med. 1985;103:964-965.
44. Meier F, Sonnichsen K, Schaumburg-Lever G, Dopfer R, Rassner G. Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins. J Am Acad Dermatol. 1993;29:334-337.
45. Caldwell JB, Yancey KB, Engler RJ, James WD. Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins. J Am Acad Dermatol. 1994;31:827-828.
46. Mohr C, Sunderkotter C, Hildebrand A, et al. Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins. Br J Dermatol. 1995;132:824-826.
47. Kimata H. High-dose gammaglobulin treatment for atopic dermatitis. Arch Dis Child. 1994;70:335-336.
48. Pons-Guiraud A. Value of Allerglobulin in the treatment of atopic dermatitis in children and young adults: a double-blind randomized study. Rev Med Interne. 1986;7:537-542.
49. Gelfand EW, Landwehr LP, Esterl B, Mazer B. Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Clin Exp Immunol. 1996;104:61-67.
50. Gupta AK, Shear NH, Sauder DN. Efficacy of human intravenous immune globulin in pyoderma gangrenosum. J Am Acad Dermatol. 1995;32:140-142.
51. Schofield JK, Tatnall FM, Leigh IM. Recurrent erythema multiforme: clinical features and treatment in a large series of patients. Br J Dermatol. 1993;128:542-545.
52. Matthiesen L, Andersson T, Vahlquist C, Selbing A. Intravenous immunoglobulin in gestational pemphigoid: the itching disappeared and skin changes healed. Lakartidningen. 1995;92:409-410.
53. Hall RP, Rico MJ, Murray JC. Autoimmune skin disease. In: Rich RR, ed. Clinical Immunology Principles and Practice. St Louis, Mo: Mosby-Year Book Inc; 1996:1316-1342.
54. Newburger JW, Takahashi M, Belser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633-1639.